Patrick McLeroth

731 total citations · 1 hit paper
12 papers, 554 citations indexed

About

Patrick McLeroth is a scholar working on Infectious Diseases, Epidemiology and Pharmacology. According to data from OpenAlex, Patrick McLeroth has authored 12 papers receiving a total of 554 indexed citations (citations by other indexed papers that have themselves been cited), including 4 papers in Infectious Diseases, 4 papers in Epidemiology and 3 papers in Pharmacology. Recurrent topics in Patrick McLeroth's work include Bacterial Identification and Susceptibility Testing (3 papers), Clostridium difficile and Clostridium perfringens research (3 papers) and Antibiotics Pharmacokinetics and Efficacy (3 papers). Patrick McLeroth is often cited by papers focused on Bacterial Identification and Susceptibility Testing (3 papers), Clostridium difficile and Clostridium perfringens research (3 papers) and Antibiotics Pharmacokinetics and Efficacy (3 papers). Patrick McLeroth collaborates with scholars based in United States, United Kingdom and Spain. Patrick McLeroth's co-authors include Amanda Paschke, Nicholas A. Kartsonis, Alison Pedley, Matthew Sims, Michelle Brown, Yu‐Chieh Lee, Jiejun Du, Michelle Brown, Dorel Săndesc and Maria C Losada and has published in prestigious journals such as New England Journal of Medicine, Clinical Infectious Diseases and Antimicrobial Agents and Chemotherapy.

In The Last Decade

Patrick McLeroth

12 papers receiving 540 citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Cefepime–Taniborbactam in Complicated Urinary Tract Infection

2024 67 citations Leanne B. Gasink, Paul C. McGovern et al. New England Journal of Medicine profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Patrick McLeroth United States	8	331	239	195	150	100	12	554
Nazaret Cobos-Trigueros Spain	14	269 0.8×	166 0.7×	241 1.2×	180 1.2×	192 1.9×	21	617
Donatella Lombardo Italy	11	289 0.9×	163 0.7×	168 0.9×	133 0.9×	66 0.7×	19	551
Jean Li Yan United States	13	234 0.7×	238 1.0×	226 1.2×	74 0.5×	58 0.6×	28	546
Lambrini Galani Greece	10	318 1.0×	199 0.8×	207 1.1×	94 0.6×	85 0.8×	14	545
Linda Bussini Italy	14	251 0.8×	153 0.6×	221 1.1×	188 1.3×	101 1.0×	34	682
Abel Jasovich Argentina	10	202 0.6×	226 0.9×	211 1.1×	89 0.6×	71 0.7×	22	439
Jung-Jr Ye Taiwan	15	206 0.6×	92 0.4×	170 0.9×	106 0.7×	84 0.8×	28	495
Kate Sulham United States	10	252 0.8×	121 0.5×	257 1.3×	161 1.1×	124 1.2×	19	487
Rachel V Marini United States	8	407 1.2×	325 1.4×	242 1.2×	183 1.2×	78 0.8×	16	588
Hande Aydemir Türkiye	11	244 0.7×	157 0.7×	276 1.4×	79 0.5×	39 0.4×	22	479

Countries citing papers authored by Patrick McLeroth

Since Specialization

Citations

This map shows the geographic impact of Patrick McLeroth's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Patrick McLeroth with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Patrick McLeroth more than expected).

Fields of papers citing papers by Patrick McLeroth

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Patrick McLeroth. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Patrick McLeroth. The network helps show where Patrick McLeroth may publish in the future.

Co-authorship network of co-authors of Patrick McLeroth

This figure shows the co-authorship network connecting the top 25 collaborators of Patrick McLeroth. A scholar is included among the top collaborators of Patrick McLeroth based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Patrick McLeroth. Patrick McLeroth is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

12 of 12 papers shown

Gasink, Leanne B., Paul C. McGovern, Greg Moeck, et al.. (2024). Cefepime–Taniborbactam in Complicated Urinary Tract Infection. New England Journal of Medicine. 390(7). 611–622. 67 indexed citations breakdown →

Niederman, Michael S., Jeff Alder, Matteo Bassetti, et al.. (2019). Inhaled amikacin adjunctive to intravenous standard-of-care antibiotics in mechanically ventilated patients with Gram-negative pneumonia (INHALE): a double-blind, randomised, placebo-controlled, phase 3, superiority trial. The Lancet Infectious Diseases. 20(3). 330–340. 87 indexed citations

McLeroth, Patrick, et al.. (2019). Effects of valganciclovir on spermatogenesis in renal transplant patients – results of a multicenter prospective nonrandomized study. Transplant International. 33(3). 310–320. 5 indexed citations

Holland, Thomas L, William O’Riordan, Alison J. McManus, et al.. (2018). A Phase 3, Randomized, Double-Blind, Multicenter Study To Evaluate the Safety and Efficacy of Intravenous Iclaprim versus Vancomycin for Treatment of Acute Bacterial Skin and Skin Structure Infections Suspected or Confirmed To Be Due to Gram-Positive Pathogens (REVIVE-2 Study). Antimicrobial Agents and Chemotherapy. 62(5). 31 indexed citations

Sims, Matthew, Patrick McLeroth, Yu‐Chieh Lee, et al.. (2017). Prospective, randomized, double-blind, Phase 2 dose-ranging study comparing efficacy and safety of imipenem/cilastatin plus relebactam with imipenem/cilastatin alone in patients with complicated urinary tract infections. Journal of Antimicrobial Chemotherapy. 72(9). 2616–2626. 126 indexed citations

Huang, David B., Patrick McLeroth, Thomas M. File, et al.. (2017). A Phase 3, Randomized, Double-Blind, Multicenter Study to Evaluate the Safety and Efficacy of Intravenous Iclaprim vs. Vancomycin in the Treatment of Acute Bacterial Skin and Skin Structure Infections Suspected or Confirmed to be Due to Gram-Positive Pathogens (REVIVE-1). Open Forum Infectious Diseases. 4(suppl_1). S536–S536. 8 indexed citations

Huang, David B., William O’Riordan, J. Scott Overcash, et al.. (2017). A Phase 3, Randomized, Double-Blind, Multicenter Study to Evaluate the Safety and Efficacy of Intravenous Iclaprim Vs Vancomycin for the Treatment of Acute Bacterial Skin and Skin Structure Infections Suspected or Confirmed to be Due to Gram-Positive Pathogens: REVIVE-1. Clinical Infectious Diseases. 66(8). 1222–1229. 41 indexed citations

Zhang, Xiaoyan M., Patrick McLeroth, Richard Berkowitz, et al.. (2016). [124I]FIAU: Human dosimetry and infection imaging in patients with suspected prosthetic joint infection. Nuclear Medicine and Biology. 43(5). 273–279. 37 indexed citations

Lucasti, Christopher, Dorel Săndesc, Donatas Venskutonis, et al.. (2016). Phase 2, Dose-Ranging Study of Relebactam with Imipenem-Cilastatin in Subjects with Complicated Intra-abdominal Infection. Antimicrobial Agents and Chemotherapy. 60(10). 6234–6243. 144 indexed citations

10.

Lucasti, Christopher, Dorel Săndesc, Donatas Venskutonis, et al.. (2015). A Phase 2 Study to Evaluate the Efficacy & Safety of Relebactam (REL) + Imipenem/Cilastatin (IMI) vs IMI Alone in Subjects with Complicated Intra-Abdominal Infection (cIAI). 1 indexed citations

11.

Shapiro, Janet & Patrick McLeroth. (2002). Status asthmaticus: a large MICU experience. Clinical Intensive Care. 13(2). 89–93. 1 indexed citations

12.

Shapiro, Janet & Patrick McLeroth. (2002). Status asthmaticus: a large MICU experience. Clinical Intensive Care. 13(2-3). 89–93. 6 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact